IDEXX Laboratories (IDXX) Earns Media Impact Rating of 0.15
Headlines about IDEXX Laboratories (NASDAQ:IDXX) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. IDEXX Laboratories earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.1339129482152 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern’s rankings:
- Insider Selling: IDEXX Laboratories, Inc. (NASDAQ:IDXX) Chairman Sells 17,000 Shares of Stock (americanbankingnews.com)
- $493.63 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter (americanbankingnews.com)
- IDEXX Laboratories, Inc. (IDXX) Stake Down in Latest Report from Neuberger Berman Group LLC (modernreaders.com)
- See what the IHS Markit Score report has to say about Idexx Laboratories Inc. (finance.yahoo.com)
- Insider Activity – IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Modern Readers (modernreaders.com)
IDEXX Laboratories (NASDAQ IDXX) traded down 2.23% on Thursday, hitting $151.06. The company’s stock had a trading volume of 912,673 shares. The firm has a 50 day moving average of $162.05 and a 200 day moving average of $155.37. The firm has a market cap of $13.18 billion, a price-to-earnings ratio of 51.96 and a beta of 0.49. IDEXX Laboratories has a 12 month low of $102.45 and a 12 month high of $173.01.
IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, August 1st. The company reported $0.95 EPS for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.10. The business had revenue of $508.90 million for the quarter, compared to analyst estimates of $502.44 million. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period last year, the company posted $0.74 earnings per share. Equities research analysts forecast that IDEXX Laboratories will post $3.18 earnings per share for the current fiscal year.
IDEXX Laboratories declared that its Board of Directors has approved a share buyback program on Wednesday, May 3rd that authorizes the company to buyback 3,000,000 outstanding shares. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its stock is undervalued.
IDXX has been the topic of a number of research analyst reports. Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Monday, June 12th. BidaskClub upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Stifel Nicolaus upped their target price on IDEXX Laboratories from $150.00 to $185.00 and gave the stock a “buy” rating in a report on Monday, May 1st. Canaccord Genuity reiterated a “buy” rating and set a $180.00 target price (up previously from $165.00) on shares of IDEXX Laboratories in a report on Friday, April 28th. Finally, Aegis initiated coverage on IDEXX Laboratories in a report on Wednesday, May 31st. They set a “sell” rating and a $118.00 target price on the stock. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. IDEXX Laboratories presently has a consensus rating of “Hold” and an average price target of $173.80.
In other news, Chairman Jonathan W. Ayers sold 17,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $154.54, for a total transaction of $2,627,180.00. Following the transaction, the chairman now directly owns 1,039,034 shares of the company’s stock, valued at $160,572,314.36. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Lawrence D. Kingsley bought 2,000 shares of IDEXX Laboratories stock in a transaction dated Thursday, August 3rd. The shares were bought at an average cost of $151.76 per share, for a total transaction of $303,520.00. Following the completion of the transaction, the director now owns 3,344 shares of the company’s stock, valued at approximately $507,485.44. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 55,572 shares of company stock worth $8,844,817. Corporate insiders own 2.77% of the company’s stock.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.